SCHEMBL10104023

SCHEMBL10104023

COc1cccc(CNC(=O)c2c(C)n(Cc3ccccc3)c3ccccc23)c1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.72
PPARG P37231 1/20 0.59
PLA2G2A P14555 4/20 0.57
RXFP1 Q9HBX9 2/20 0.55
S1PR3 Q99500 2/20 0.55
CNR2 P34972 1/20 0.55
MMP13 P45452 1/20 0.54
PLA2G1B P04054 1/20 0.53
F10 P00742 1/20 0.53
ALDH1A1 P00352 2/20 0.53
RAB9A P51151 1/20 0.53
GAA P10253 1/20 0.53
PKM P14618 1/20 0.53
TP53 P04637 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KDM4E B2RXH2 1/20 0.52
USP2 O75604 1/20 0.52
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805691 0.91 MAPT (0.69) MAPTPPARGPLA2G2ARXFP1S1PR3
SCHEMBL805678 0.87 MAPT (0.57) MAPTPPARGRXFP1CNR2MMP13
SCHEMBL805670 0.85 S1PR3 (0.59) MAPTS1PR3CNR2F10ALDH1A1
SCHEMBL805701 0.82 S1PR3 (0.76) S1PR3
SCHEMBL805711 0.81 S1PR3 (0.58) MAPTS1PR3F10ALDH1A1GAA
SCHEMBL805632 0.79 MAPT (0.59) MAPTPPARGPLA2G2ARXFP1S1PR3
SCHEMBL805735 0.79 S1PR3 (0.73) MAPTS1PR3
SCHEMBL10103999 0.79 MAPT (0.54) MAPTPPARGPLA2G2AS1PR3MMP13
SCHEMBL16344540 0.78 GAA (0.77) MAPTPLA2G2APLA2G1BF10ALDH1A1
SCHEMBL5543791 0.77 CNR2 (0.58) MAPTCNR2MMP13ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140011771-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN ALLERGAN, INC. (US) 2014-01-09 US disclosed
US-8563594-B2 S1P3 receptor inhibitors for treating pain ALLERGAN, INC. (US) 2013-10-22 US disclosed
US-8563594-B2 S1P3 receptor inhibitors for treating pain ALLERGAN, INC. (US) 2013-10-22 US disclosed
US-20120071448-A1 S1P3 Receptor Inhibitors for Treating Conditions of the Eye ALLERGAN, INC. (US) 2012-03-22 US disclosed
US-20110009453-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION DONELLO JOHN E 2011-01-13 US disclosed
WO-2010129553-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING CONDITIONS OF THE EYE ALLERGAN, INC. (US) 2010-11-11 WO disclosed
US-20100249069-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN DONELLO JOHN E 2010-09-30 US disclosed
US-20100249069-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN DONELLO JOHN E 2010-09-30 US disclosed
US-7737173-B2 Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN, INC. (US) 2010-06-15 US disclosed
US-7737173-B2 Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN, INC. (US) 2010-06-15 US disclosed
WO-2009117335-A2 S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION ALLERGAN, INC. (US) 2009-09-24 WO disclosed
WO-2008141013-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN ALLERGAN, INC. (US) 2008-11-20 WO disclosed
WO-2007095561-A2 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2007-08-23 WO disclosed
US-20070191313-A1 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2007-08-16 US disclosed
US-20070191313-A1 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011771-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN S1PR3, LPAR3, S1PR2 MAPT 3312/4885PPARG 1636/4885PLA2G2A 188/4885
US-20110009453-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION S1PR3, S1PR1, S1PR2 MAPT 2739/4885PPARG 1293/4885PLA2G2A 254/4885
US-20120071448-A1 S1P3 Receptor Inhibitors for Treating Conditions of the Eye S1PR3, S1PR1, S1PR2 MAPT 3541/4885PPARG 1430/4885PLA2G2A 92/4885
US-20100249069-A1 S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN S1PR3, LPAR3, S1PR2 MAPT 3312/4885PPARG 1636/4885PLA2G2A 188/4885
US-20070191313-A1 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY S1PR3, S1PR1, S1PR2 MAPT 4447/4885PPARG 577/4885PLA2G2A 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.